Ellis Giovanina M, Page Libby C, Burman Blaire E, Buskin Susan, Frenkel Lisa M
Department of Infections and Prematurity, Seattle Children's Hospital and Research Institute, Seattle, WA, USA.
J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):283-9. doi: 10.1097/QAI.0b013e3181a9972c.
HIV-1 drug resistance has been detected in 8%-24% of recently infected North Americans when assessed by consensus sequencing of plasma. We hypothesized that rates were likely higher but not detected because drug-resistant mutants are transmitted or regressed to levels below the limit of detection by consensus sequencing of HIV-1 RNA.
Specimens from antiretroviral-naive individuals recently diagnosed with HIV-1 infection were compared at 15 codons to determine if testing of DNA using a sensitive oligonucleotide ligation assay (OLA) would detect drug resistance mutants not evident by consensus sequencing of serum.
HIV-1 drug resistance at 15 major resistance codons was greater by OLA compared with consensus sequencing: 18 of 104 vs. 12 of 104 individuals (P < or = 0.008) and 33 vs. 18 total mutations (P < or = 0.001); increasing the rate of detection at these 15 codons by 83%. Additional mutations were detected by consensus sequencing at L33, M46, D67, V108, and K219 that were not assessed by OLA.
The increased detection of drug-resistant HIV-1 by testing peripheral blood cells with a sensitive assay implies that both low and high levels of drug-resistant mutants are transmitted or persist in antiretroviral-naive individuals, suggesting that the clinical relevance of mutants persisting at both levels should be evaluated.
通过血浆的一致性测序评估发现,8% - 24%的近期感染的北美人体内存在HIV - 1耐药性。我们推测实际发生率可能更高,但未被检测到,因为耐药突变体在传播过程中或通过HIV - 1 RNA的一致性测序回归到低于检测限的水平。
对近期诊断为HIV - 1感染且未接受抗逆转录病毒治疗的个体的样本进行15个密码子的比较,以确定使用灵敏的寡核苷酸连接测定法(OLA)检测DNA是否能发现血清一致性测序未显示的耐药突变体。
与一致性测序相比,通过OLA检测到的15个主要耐药密码子处的HIV - 1耐药性更高:104名个体中有18名(一致性测序为12名)(P≤0.008),总突变数为33个(一致性测序为18个)(P≤0.001);这15个密码子的检测率提高了83%。通过一致性测序在L33、M46、D67、V108和K219处检测到了OLA未评估的其他突变。
通过灵敏检测法检测外周血细胞增加了耐药HIV - 1的检出率,这意味着低水平和高水平的耐药突变体在未接受抗逆转录病毒治疗的个体中都会传播或持续存在,这表明应评估这两种水平持续存在的突变体的临床相关性。